

MORGAN L. FITCH, JR.
FRANCIS A. EVEN*
JULIUS TABIN
JOHN F. FLANNERY
ROBERT B. JONES
JAMES J. SCHUMANN
JAMES J. HAMILL
TIMOTHY E. LEVSTIK
JOSEPH E. SHIPLEY
KENNETH H. SAMPLES
PHILIP T. PETTI
JOSEPH T. NABOR
STEVEN C. SCHROER
RICHARD A. KABA*
KARL R. FINK
MARK W. HETZLER
TIMOTHY P. MALONEY
JAMES P. KRUEGER
STEPHEN S. FAVAKEH
RICHARD E. WAWRZYNIAK
STEVEN G. PARMELEE
THOMAS F. LEBENS
BRUCE R. MANSFIELD
KENDREW H. COLTON*
G. PAUL EDGELL*
MICHAEL A. SANZO*
SCOTT A. MENGHINI
NORMAN N. KUNITZ*
RUDY KRATZ
RAMON R. HOCH*



FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

Established in 1859

SUITE 401L - 1801 K STREET, NW
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LASALLE STREET, CHICAGO, ILLINOIS 60603-3406
TELEPHONE (312) 577-7000

CALIFORNIA OFFICE

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7708
TELEPHONE (858) 552-1311

COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302
TELEPHONE (303) 402-6966

March 31, 2004

EDWARD E. CLAIR
JON A. BIRMINGHAM
JOHN E. LYHUS
STEVEN M. FREELAND
DONNA E. BECKER
MICHAEL G. VRANICAR
BRIAN S. CLISE
MARTIN R. BADER
DEREK L. PRESTIN
MARK A. BORSOS
DAVID R. JAGLOWSKI
TIMOTHY R. BAUMANN
JEFFREY A. CHELSTROM
NICHOLAS T. PETERS
KENNETH A. PLOCHINSKI
MEGAN J. REDMOND

PATENT AGENTS

ERIC J. WHITESELL
LILIA I. SAFONOV

OF COUNSEL

GEORGE W. SPELLMIRE, JR.
LISA M. SOMMER
GEORGE H. SPENCER, P.C.*

TECHNICAL ADVISOR

JOHN M. BRONK, PH.D.

*ADMITTED TO D.C. BAR; D.C. PRACTICE OF
ALL OTHERS LIMITED TO FEDERAL COURTS
AND AGENCIES

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Re: Amendment and Response
Appl. No.: 09/873,409
Filed: June 5, 2001
Title: **A Gene Encoding a Multidrug Resistance
Human P-Glycoprotein Homologue on
Chromosome 7p15-21 and Uses Thereof**
Inventor(s): Frank, *et al.*
Atty. Dkt.: 7570/73298 (formerly 81994/279322)

Dear Sir:

The following documents are being forwarded herewith for appropriate action by the U.S.
Patent and Trademark Office:

1. Amendment and Response Under 37 C.F.R. § 1.111; and
2. One return postcard.

Assistant Commissioner for Patents

March 31, 2004

Page 2

CALCULATION OF ADDITIONAL FEES

Applicant(s) have calculated additional fees as follows:

	No. After Amendment	No. Previously Paid for	No. Extra	Rate	Fee
Total Claims Fee	24	25 =	0	\$ 18.00	0.00
Independent Claims Fee	4	5 =	0	\$ 78.00	0.00
Multiple Dependent Claims Fee (Previously Paid)	0	0	0	\$ 280.00	0.00
Total Additional Claims Fee					0.00
Extension of Time Fee					0.00
TOTAL FEES DUE					0.00

As indicated above, Applicants do not believe that any fees are due for the filing of this response. However, The Commissioner is hereby authorized to charge any fee deficiency with respect to this filing and any other fee required in connection with the present case, or credit any overpayment, to our Deposit Account No. 06-1135 under Order No. 7570/73298.

It is respectfully requested that the enclosed postcard be stamped with the date the enclosed documents are received by the PTO and that it be returned as soon as possible.

Very truly yours,

FITCH, EVEN, TABIN & FLANNERY



Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

MAS:ct
Enclosures



41

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Frank, *et al.*

Appl. No.: 09/873,409

Filed: June 5, 2001

For: **A Gene Encoding a Multidrug Resistance
Human P-Glycoprotein Homologue on
Chromosome 7p15-21 and Uses Thereof**

Group Art Unit: 1642

Examiner: Yu, M.

Atty. Dkt. 7570/73298
(Formerly 81994/279322)

Amendment and Response Under 37 C.F.R. §1.111

Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

In response to the Office Action dated December 31, 2003, Applicants respectfully request reconsideration of the above-captioned application in view of the following amendments and remarks.

Amendments to the Claims begin on page 2 of the present document.

Remarks/Arguments begin on page 4 of the present document.